febuxostat has been researched along with Fibrosis in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (77.78) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Alqahtani, A; Balakumar, P; Dhanaraj, SA; Khan, NA; Mahadevan, N | 1 |
| Aonuma, K; Duo, F; Ieda, M; Li, S; Mori, H; Murakata, Y; Murakoshi, N; Nogami, A; Okabe, Y; Sato, A; Shimoda, Y; Song, Z; Tajiri, K; Xu, D; Yuan, Z | 1 |
| Ako, J; Fukaya, H; Igarashi, T; Kishihara, J; Murakami, M; Nakamura, H; Niwano, H; Niwano, S; Oikawa, J; Satoh, A; Tamaki, H; Yoshizawa, T | 1 |
| Ito, O; Kohzuki, M; Kurosawa, R; Miura, T; Nakamura, T; Namai-Takahashi, A; Sakuyama, A; Takahashi, J | 1 |
| Chuma, M; Fujino, H; Fukushima, K; Goda, M; Horinouchi, Y; Ikeda, Y; Ikuto, R; Imanishi, M; Ishizawa, K; Izawa-Ishizawa, Y; Kondo, M; Murai, Y; Takechi, K; Tsuchiya, K; Zamami, Y | 1 |
| Asano, T; Fujishiro, M; Inoue, MK; Inoue, Y; Kushiyama, A; Masaki, T; Matsunaga, Y; Morii, K; Nakatsu, Y; Ono, H; Sakoda, H; Sasaki, K; Suzuki, Y; Ueda, K; Yamamotoya, T | 1 |
| Cicalese, S; Eguchi, S; Scalia, R | 1 |
| Cao, J; Li, H; Li, R; Li, Y; Peng, Y; Xia, A; Zhang, Y | 1 |
| Inoue, K; Isaka, Y; Kaimori, J; Kawada, N; Matsui, I; Moriyama, T; Omori, H; Rakugi, H; Takabatake, Y; Ueda, Y; Yamamoto, R | 1 |
1 review(s) available for febuxostat and Fibrosis
| Article | Year |
|---|---|
Mechanistic insights into hyperuricemia-associated renal abnormalities with special emphasis on epithelial-to-mesenchymal transition: Pathologic implications and putative pharmacologic targets.
Topics: Animals; Biomarkers; Cytokines; Epithelial-Mesenchymal Transition; Febuxostat; Fibrosis; Gout Suppressants; Humans; Hyperuricemia; Inflammation Mediators; Kidney; Kidney Diseases; Oxidative Stress; Signal Transduction; Uric Acid | 2020 |
8 other study(ies) available for febuxostat and Fibrosis
| Article | Year |
|---|---|
Xanthine oxidase inhibitor febuxostat reduces atrial fibrillation susceptibility by inhibition of oxidized CaMKII in Dahl salt-sensitive rats.
Topics: Allopurinol; Animals; Atrial Fibrillation; Calcium Signaling; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Connexins; Disease Models, Animal; Enzyme Inhibitors; Febuxostat; Fibrosis; Gap Junction alpha-5 Protein; Gap Junctions; Hypertension; Male; Myocytes, Cardiac; Oxidation-Reduction; Phosphorylation; Rats, Inbred Dahl; Ryanodine Receptor Calcium Release Channel; Sodium Chloride, Dietary; Xanthine Oxidase | 2021 |
Antiremodeling Effect of Xanthine Oxidase Inhibition in a Canine Model of Atrial Fibrillation.
Topics: Animals; Antioxidants; Atrial Fibrillation; Atrial Remodeling; Disease Models, Animal; Dogs; Echocardiography; Febuxostat; Female; Fibronectins; Fibrosis; Gout Suppressants; Heart Atria; Hemodynamics; Oxidative Stress; Reactive Oxygen Species; Xanthine Oxidase | 2018 |
Xanthine Oxidase Inhibitor, Febuxostat Ameliorates the High Salt Intake-Induced Cardiac Hypertrophy and Fibrosis in Dahl Salt-Sensitive Rats.
Topics: Animals; Collagen; Disease Models, Animal; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Febuxostat; Fibrosis; Heart Ventricles; Hypertrophy, Left Ventricular; Male; NADPH Oxidases; Phosphorylation; Rats, Inbred Dahl; Reactive Oxygen Species; Renin-Angiotensin System; Sodium Chloride, Dietary; Transforming Growth Factor beta1; Ventricular Function, Left; Ventricular Remodeling; Xanthine Oxidase | 2019 |
Xanthine Oxidase Inhibition by Febuxostat in Macrophages Suppresses Angiotensin II-Induced Aortic Fibrosis.
Topics: Actins; Adventitia; Angiotensin II; Animals; Aorta; Aortic Diseases; Disease Models, Animal; Febuxostat; Fibroblasts; Fibrosis; Gout Suppressants; Hypertension; Macrophages; Male; Mice, Inbred C57BL; Transforming Growth Factor beta1; Vascular Remodeling; Xanthine Oxidase | 2019 |
The Xanthine Oxidase Inhibitor Febuxostat Suppresses the Progression of IgA Nephropathy, Possibly via Its Anti-Inflammatory and Anti-Fibrotic Effects in the gddY Mouse Model.
Topics: Animals; Anti-Inflammatory Agents; Chemokines; Disease Progression; Endoplasmic Reticulum Stress; Febuxostat; Female; Fibrosis; Gene Expression Regulation; Glomerulonephritis, IGA; Inflammation Mediators; Kidney; Mice, Inbred BALB C; Xanthine Oxidase | 2018 |
Xanthine Oxidase Inhibition as a Potential Treatment for Aortic Stiffness in Hypertension.
Topics: Angiotensin II; Febuxostat; Fibrosis; Humans; Hypertension; Macrophages; Vascular Stiffness; Xanthine Oxidase | 2019 |
Febuxostat Prevents Renal Interstitial Fibrosis by the Activation of BMP-7 Signaling and Inhibition of USAG-1 Expression in Rats.
Topics: Animals; Bone Morphogenetic Protein 7; Febuxostat; Fibrosis; Intracellular Signaling Peptides and Proteins; Kidney; Male; Proteins; Random Allocation; Rats; Rats, Sprague-Dawley; Signal Transduction; Ureteral Obstruction | 2015 |
Use of xanthine oxidase inhibitor febuxostat inhibits renal interstitial inflammation and fibrosis in unilateral ureteral obstructive nephropathy.
Topics: Animals; Cell Movement; Cytokines; Disease Models, Animal; Febuxostat; Fibrosis; Kidney; Kidney Diseases; Macrophages; Male; Nephritis, Interstitial; Oxidative Stress; Rats; Rats, Sprague-Dawley; Thiazoles; Transforming Growth Factor beta; Ureteral Obstruction; Xanthine Oxidase | 2012 |